Matthew Hanson, MD
Dermatology · Newark, DENPI 1285896829
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 29.1% of the total. Reporting peaked in 2019 at $1,289 and has fallen 54.0% since, to $593 in 2025. That places this record below the midpoint for dermatology clinicians in DE, where the typical reported total is $5,548.
Across 216 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$501
- Johnson & Johnson$318
- Dermavant Sciences, Inc.$276
- LEO Pharma Inc.$223
- Pfizer$177
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,74098%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,115 |
| Novartis | 24 | $501 |
| Johnson & Johnson | 19 | $318 |
| Dermavant Sciences, Inc. | 17 | $276 |
| LEO Pharma Inc. | 13 | $223 |
| Pfizer | 11 | $177 |
| UCB, Inc. | 8 | $167 |
| E.r. Squibb & Sons, L.L.C. | 10 | $165 |
| Sanofi | 8 | $146 |
| Regeneron Healthcare Solutions, Inc. | 8 | $130 |
| Incyte Corporation | 5 | $122 |
| Lilly USA, LLC | 7 | $93 |
| Bristol Myers Squibb | 4 | $88 |
| Amgen | 3 | $54 |
| Organon | 2 | $40 |
| Galderma Laboratories, L.p. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 3 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Genentech USA, Inc. | 2 | $22 |
| VYNE Pharmaceuticals Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Biofrontera Inc. | 1 | $16 |
| Strata Skin Sciences, Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Almirall LLC | 1 | $14 |
How this compares
$3,834 in reported general payments places this provider in the 45th percentile of 23 dermatology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $71,661 |
| OraceaDoxycycline Monohydrate | 11 | $15,911 |
| JubliaEfinaconazole | 19 | $14,488 |
| Tacrolimus | 44 | $6,985 |
| Metronidazole | 84 | $5,316 |
| Clobetasol Propionate | 93 | $5,023 |
| Ketoconazole | 175 | $3,456 |
| Doxycycline Hyclate | 78 | $2,757 |
| Calcipotriene | 13 | $2,424 |
| Triamcinolone Acetonide | 163 | $2,167 |
| Betamethasone Valerate | 18 | $1,998 |
| Tretinoin | 20 | $1,919 |
| Fluorouracil | 19 | $1,268 |
| Gentamicin Sulfate | 24 | $1,262 |
| Clindamycin Phosphate | 42 | $1,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Galderma Laboratories, L.p.Oracea | $37 | $15,91111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 23 dermatology providers in Delaware.
Other dermatology in Newark
- Kiera BoothNewark$50K
- Thomas BurkeNewark$21K
- Gina CaputoNewark$13K
- Lori SpencerNewark$13K
- Helen MashekNewark$9K
- Dawn HirokawaNewark$6K
- Hannah AndersonNewark$2K
- Peter PanzerNewark$201
- Guy WebsterHockessin$52K
- Michael RosenthalWilmington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.